127 related articles for article (PubMed ID: 34292567)
1. Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues.
Gut P; Czarnywojtek A; Sawicka-Gutaj N; Woliński K; Maciejewski A; Komarnicki P; Ruchała M
Endokrynol Pol; 2021; 72(4):308-318. PubMed ID: 34292567
[TBL] [Abstract][Full Text] [Related]
2. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects.
Isgrò MA; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():125-43. PubMed ID: 26530364
[TBL] [Abstract][Full Text] [Related]
3. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
Gut P; Ruchała M
Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A assessment in patients with neuroendocrine neoplasm of the small bowel and carcinoid syndrome treated with somatostatin analogues.
Gut P; Czarnywojtek A; Ruchała M
Adv Clin Exp Med; 2020 Nov; 29(11):1319-1324. PubMed ID: 33269818
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of neuron-specific enolase as a prognostic factor for disease progression in patients with GET/NEN in the pancreas and the small intestine.
Fuksiewicz M; Kowalska M; Kolasinska-Cwikla A; Kotowicz B
Endocr Connect; 2022 Sep; 11(9):. PubMed ID: 35900770
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
9. Role of the ratio of NSE serum concentration in evaluating the therapeutic effect on metastatic neuroendocrine neoplasms of the liver.
Kan J; Tian Y; Shao Y; Xu H; Li X; Tang Q
Tumori; 2022 Apr; 108(2):157-164. PubMed ID: 33759643
[TBL] [Abstract][Full Text] [Related]
10. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
11. Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours.
Fizazi K; Farhat F; Theodore C; Rixe O; Le Cesne A; Comoy E; Le Chevalier T
Br J Cancer; 1997; 75(1):76-8. PubMed ID: 9000601
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
17. [The value of neuron specific enolase (NSE) in patients with brain tumors].
Taomoto K; Kokunai T; Okuda T; Tamaki N; Matsumoto S; Hashimoto N
No To Shinkei; 1987 Feb; 39(2):169-73. PubMed ID: 3828153
[TBL] [Abstract][Full Text] [Related]
18. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
[TBL] [Abstract][Full Text] [Related]
19. Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.
Mjønes P; Sagatun L; Nordrum IS; Waldum HL
J Histochem Cytochem; 2017 Dec; 65(12):687-703. PubMed ID: 28972818
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]